

**GOVERNMENT OF INDIA
MINISTRY OF HEALTH AND FAMILY WELFARE
DEPARTMENT OF HEALTH AND FAMILY WELFARE**

**LOK SABHA
UNSTARRED QUESTION NO.298
TO BE ANSWERED ON 21ST JULY, 2023**

RISING PRICES OF LIFE SAVING MEDICINES

298: SHRI KUMBAKUDI SUDHAKARAN:

Will the Minister of **HEALTH AND FAMILY WELFARE** be pleased to state:

- (a) Whether the Government has taken note of rising prices of life-saving medicines in the country including R CINEX E;
- (b) If so, the details thereof and if not, the reasons therefor;
- (c) The steps taken/proposed to be taken by the government to control the prices of such life-saving medicines; and
- (d) if so, the details thereof?

ANSWER

**THE MINISTER OF STATE IN THE MINISTRY OF HEALTH AND
FAMILY WELFARE
(DR. BHARATI PRAVIN PAWAR)**

(a) & (b): As informed by Department of Pharmaceuticals (DoP), it notifies Schedule-I of Drugs (Prices Control) Order (DPCO) based on the National List of Essential Medicines (NLEM).

National Pharmaceutical Pricing Authority (NPPA) under DoP fixes the Ceiling Price of these scheduled medicines specified in the Schedule-I of the DPCO, 2013. Further, as per the para 20 of DPCO, 2013, the manufacturers of non-scheduled formulations are not allowed to increase the maximum retail price of such formulations by more than 10% per annum.

The formulations under Schedule-I are categorized according to their therapeutic categories and as R CINEX E is a non-scheduled formulation, its price has not been fixed by NPPA. However, as per the market database available with NPPA, no violation under Para 20 has been observed, nor any public grievance has been received for price hike of more than 10% for R CINEX E.

(c) & (d): NPPA has fixed ceiling prices of 915 scheduled formulations till 17.07.2023. The details of prices fixed by NPPA are available on the website of NPPA i.e., nppaindia.nic.in.
